Malik Muhammad K, Kinno Menhel, Liebo Max, Yu Mingxi D, Syed Mushabbar
Department of Internal Medicine, Loyola University Medical Center, Maywood, IL, United States.
Department of Cardiology, Baylor Scott & White, The Heart Hospital, Plano, TX, United States.
Front Cardiovasc Med. 2025 Apr 23;12:1573346. doi: 10.3389/fcvm.2025.1573346. eCollection 2025.
Heart failure with preserved ejection fraction (HFpEF) is a complex clinical diagnosis with a heterogeneous pathophysiology and clinical presentation. The hallmark of HFpEF is diastolic dysfunction associated with left ventricular remodeling and fibrosis. Myocardial interstitial fibrosis (MIF) occurs as the result of collagen deposition and is dependent on the underlying etiology of heart failure. Detection of MIF can be done by invasive histopathologic sampling or by imaging. More recently, novel biomarkers have been investigated as an alternative tool for not only the detection of MIF but also for the prognostication of patients with HFpEF which may in turn alleviate the need for invasive and expensive imaging in the future.
射血分数保留的心力衰竭(HFpEF)是一种复杂的临床诊断,其病理生理学和临床表现具有异质性。HFpEF的标志是与左心室重构和纤维化相关的舒张功能障碍。心肌间质纤维化(MIF)是胶原蛋白沉积的结果,取决于心力衰竭的潜在病因。MIF的检测可以通过侵入性组织病理学采样或成像来完成。最近,新型生物标志物已被研究作为一种替代工具,不仅用于检测MIF,还用于HFpEF患者的预后评估,这反过来可能会减少未来对侵入性和昂贵成像的需求。